Based on 17 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $91.93 with a high forecast of $130.00 and a low forecast of $48.00. The average price target represents a 103.34% change from the last price of $45.21.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","131":"$131","58.25":"$58.3","82.5":"$82.5","106.75":"$106.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$130.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":91.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$91.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,58.25,82.5,106.75,131],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.46,56.57846153846154,62.69692307692308,68.81538461538462,74.93384615384615,81.05230769230769,87.17076923076922,93.28923076923076,99.4076923076923,105.52615384615385,111.64461538461538,117.76307692307691,123.88153846153844,{"y":130,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.46,53.65,56.84,60.03,63.22,66.41,69.6,72.79,75.98,79.17,82.36000000000001,85.55000000000001,88.74000000000001,{"y":91.93,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.46,50.27076923076923,50.081538461538464,49.892307692307696,49.70307692307692,49.51384615384615,49.324615384615385,49.135384615384616,48.94615384615385,48.75692307692308,48.567692307692305,48.378461538461536,48.18923076923077,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.875,"date":1682035200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.028,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.515,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.88,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.81,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.7,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.491,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.39,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.83,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.976,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.752,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.295,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.46,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$130.00

Average Price Target$91.93

Lowest Price Target$48.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

TD Cowen

xxxxxxxxxxxxx

Reiterated

04/24/24

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

xxxxxxxxxxxxx

Reiterated

04/23/24

xxxxxxxxxxxxxxxxxx

Piper Sandler

xxxxxxxxxxxxx

Reiterated

04/22/24

xxxxxxxxxxxxxxxxxx

Bank of America Securities

xxxxxxxxxxxxx

Reiterated

04/22/24

xxxxxxxxxxxxxxxxxx

RBC Capital

xxxxxxxxxxxxx

Initiated

04/22/24

xxxxxxxxxxxxxxxxxx

Jefferies

xxxxxxxxxxxxx

Reiterated

04/16/24

xxxxxxxxxxxxxxxxxx

Wedbush

xxxxxxxxxxxxx

Reiterated

04/16/24

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Reiterated

04/15/24

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Reiterated

04/15/24

xxxxxxxxxxxxxxxxxx

Wells Fargo

xxxxxxxxxxxxx

Reiterated

04/14/24

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

04/11/24

Optimistic Outlook for Ultragenyx Pharmaceutical with a Strong Buy Rating Based on Promising Pipeline and Key Treatment Updates

Jeffrey Hung

Morgan Stanley

$65.00

Buy

43.77%

Upside

Reiterated

03/14/24

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Cannabist Company Holdings (Other OTC: CBSTF)

Kristen Kluska

Cantor Fitzgerald

$107.00

Buy

136.67%

Upside

Reiterated

02/26/24

Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Rocket Pharmaceuticals (RCKT)

Whitney Ijem

Canaccord Genuity

$111.00

Buy

145.52%

Upside

Reiterated

02/20/24

Ultragenyx Pharmaceutical: A Strong Buy on Robust Crysvita Sales and Promising Pipeline Prospects

Ed Arce

H.C. Wainwright

$82.00

Buy

81.38%

Upside

Reiterated

02/16/24

Ultragenyx Pharmaceutical's Promising Clinical Trials Underpin Buy Rating

Best Analysts Covering Ultragenyx Pharmaceutical

Which Analyst Should I Follow If I Want to Buy GB:0LIF and Sell After:

1 Month

Gena WangBarclays

Success Rate

16/26 ratings generated profit

Average Return

+3.43%

reiterated a buy rating 2 months ago

Copying Gena Wang's trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +3.43% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Yigal NochomovitzCiti

Success Rate

10/17 ratings generated profit

Average Return

+1.03%

reiterated a buy rating 10 days ago

Copying Yigal Nochomovitz's trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +1.03% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Yigal NochomovitzCiti

Success Rate

10/17 ratings generated profit

Average Return

+2.51%

reiterated a buy rating 10 days ago

Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +2.51% per trade.

2 Years

Yaron WerberTD Cowen

Success Rate

11/16 ratings generated profit

Average Return

+39.52%

reiterated a buy rating yesterday

Copying Yaron Werber's trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +39.52% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0LIF Analyst Recommendation Trends

Rating

Dec 23

Jan 24

Feb 24

Mar 24

Apr 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0LIF has received 32 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 0LIF average Analyst price target in the past 3 months is $91.93.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0LIF Financial Forecast

0LIF Earnings Forecast

Next quarter’s earnings estimate for 0LIF is -$1.75 with a range of -$2.04 to -$1.40. The previous quarter’s EPS was -$1.52. 0LIF beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 36.00% of the time in the same period. In the last calendar year 0LIF has Underperformed its overall industry.

0LIF Sales Forecast

Next quarter’s sales forecast for 0LIF is $116.38M with a range of $98.80M to $125.00M. The previous quarter’s sales results were $127.39M. 0LIF beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.84% of the time in the same period. In the last calendar year 0LIF has Outperformed its overall industry.

0LIF Stock Forecast FAQ

What is GB:0LIF’s average 12-month price target, according to analysts?

Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is $91.93.

What is GB:0LIF’s upside potential, based on the analysts’ average price target?

Ultragenyx Pharmaceutical has 103.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ultragenyx Pharmaceutical a Buy, Sell or Hold?

Ultragenyx Pharmaceutical has a conensus rating of Strong Buy, which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ultragenyx Pharmaceutical’s share price target?

The average share price target for Ultragenyx Pharmaceutical is $91.93. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $130.00 ,and the lowest forecast is $48.00. The average share price target represents 103.34% Increase from the current price of $45.21.

What do analysts say about Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of Ultragenyx Pharmaceutical?

To buy shares of GB:0LIF, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ultragenyx Pharmaceutical (0LIF) Share Forecast & Price Target

0LIF Analyst Ratings

0LIF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ultragenyx Pharmaceutical

0LIF Analyst Recommendation Trends

0LIF Financial Forecast

0LIF Earnings Forecast

0LIF Sales Forecast

0LIF Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts